224 related articles for article (PubMed ID: 20496538)
1. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Mantovani G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):292-301. PubMed ID: 20496538
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
Mantovani G; Macciò A; Madeddu C; Serpe R; Massa E; Dessì M; Panzone F; Contu P
Oncologist; 2010; 15(2):200-11. PubMed ID: 20156909
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Madeddu C; Dessì M; Panzone F; Serpe R; Antoni G; Cau MC; Montaldo L; Mela Q; Mura M; Astara G; Tanca FM; Macciò A; Mantovani G
Clin Nutr; 2012 Apr; 31(2):176-82. PubMed ID: 22047681
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.
Macciò A; Madeddu C; Gramignano G; Mulas C; Floris C; Sanna E; Cau MC; Panzone F; Mantovani G
Gynecol Oncol; 2012 Mar; 124(3):417-25. PubMed ID: 22198049
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Wen HS; Li X; Cao YZ; Zhang CC; Yang F; Shi YM; Peng LM
Chemotherapy; 2012; 58(6):461-7. PubMed ID: 23406994
[TBL] [Abstract][Full Text] [Related]
7. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
[TBL] [Abstract][Full Text] [Related]
8. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
Jatoi A; Rowland K; Loprinzi CL; Sloan JA; Dakhil SR; MacDonald N; Gagnon B; Novotny PJ; Mailliard JA; Bushey TI; Nair S; Christensen B;
J Clin Oncol; 2004 Jun; 22(12):2469-76. PubMed ID: 15197210
[TBL] [Abstract][Full Text] [Related]
9. [Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome].
Krznarić Z; Juretić A; Samija M; Dintinjana RD; Vrdoljak E; Samarzija M; Kolacek S; Vrbanec D; Prgomet D; Ivkić M; Zelić M;
Lijec Vjesn; 2007 Dec; 129(12):381-6. PubMed ID: 18383739
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD
J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract][Full Text] [Related]
12. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Lusso MR; Serpe R; Massa E; Astara G; Deiana L
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1030-4. PubMed ID: 16702388
[TBL] [Abstract][Full Text] [Related]
13. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial.
Simons JP; Schols AM; Hoefnagels JM; Westerterp KR; ten Velde GP; Wouters EF
Cancer; 1998 Feb; 82(3):553-60. PubMed ID: 9452274
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
Gramignano G; Lusso MR; Madeddu C; Massa E; Serpe R; Deiana L; Lamonica G; Dessì M; Spiga C; Astara G; Macciò A; Mantovani G
Nutrition; 2006 Feb; 22(2):136-45. PubMed ID: 16459226
[TBL] [Abstract][Full Text] [Related]
15. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.
Bruera E; Ernst S; Hagen N; Spachynski K; Belzile M; Hanson J; Summers N; Brown B; Dulude H; Gallant G
Cancer Prev Control; 1998 Apr; 2(2):74-8. PubMed ID: 9765767
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate in the management of cancer cachexia.
Madeddu C; Macciò A; Panzone F; Tanca FM; Mantovani G
Expert Opin Pharmacother; 2009 Jun; 10(8):1359-66. PubMed ID: 19445562
[TBL] [Abstract][Full Text] [Related]
19. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
20. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.
Mantovani G; Madeddu C; Macciò A; Gramignano G; Lusso MR; Massa E; Astara G; Serpe R
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1651-9. PubMed ID: 15466983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
